Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT04976309 Recruiting - Healthy Clinical Trials

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Start date: July 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel dilation in a headache model.

NCT ID: NCT04972591 Recruiting - Healthy Clinical Trials

Follow-up Study of Population Vaccinated With COVID-19 Vaccine

Start date: March 15, 2021
Phase:
Study type: Observational

A multi-centered clinical follow-up study to investigate the long-term dynamic of COVID-19 antibody level after vaccination.

NCT ID: NCT04972188 Recruiting - Healthy Clinical Trials

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

Start date: July 12, 2021
Phase: Phase 1
Study type: Interventional

ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway. ZYIL1 is expected to show benefit in patients demonstrating cytokine, like IL1β flare, including those exhibiting cytokine storm related to COVID-19 and other viral inflammatory diseases.

NCT ID: NCT04971746 Recruiting - Healthy Clinical Trials

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Start date: July 19, 2021
Phase: Phase 1
Study type: Interventional

The main aim of this study is to investigate the possible effect of GLPG4716 on the pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety and tolerability of GLPG4716 alone or administered simultaneously with pirfenidone or nintedanib.

NCT ID: NCT04971135 Recruiting - Healthy Clinical Trials

First-in-human Study of SAN711 in Healthy Participants

Start date: June 30, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, first-in-human, double-blind, randomized, placebo-controlled, parallel group, single ascending dose (SAD) and multiple ascending dose (MAD) study

NCT ID: NCT04969211 Recruiting - Healthy Clinical Trials

Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Start date: June 30, 2021
Phase: Phase 1
Study type: Interventional

This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers

NCT ID: NCT04967612 Recruiting - Healthy Clinical Trials

Visual Perception After Virtual Implantation

Start date: May 10, 2021
Phase: N/A
Study type: Interventional

Evaluation of visual perception through diffractive optical lens designs by virtual implantation.

NCT ID: NCT04965337 Recruiting - Healthy Clinical Trials

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Start date: July 11, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects.

NCT ID: NCT04964674 Recruiting - Healthy Clinical Trials

Psychometric Testing and Cue Utilization During Cued Visual Search

Start date: April 12, 2021
Phase: N/A
Study type: Interventional

The experimenters will examine the relationship between utilization of positive (target cue) and negative (distractor cue) templates during a cued visual search task with performance on a set of measures related to executive functions associated with attentional control: shifting, updating, and inhibition.

NCT ID: NCT04963439 Recruiting - Healthy Clinical Trials

A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants

Start date: June 24, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the rate and extent of absorption of macitentan following administration of a single oral dose of macitentan formulated as final market image (FMI) (test), compared to macitentan as the clinical service formulation (CSF) under fasted conditions in healthy adult participants.